945P Respiratory and cardiometabolic comorbidities and stage I-III non-small cell lung cancer (NSCLC) survival: A pooled analysis from the International Lung Cancer Consortium (ILCCO)

M García Pardo De Santayana,Z Jie,B.M Ryan,H Tindle,P Brennan,D Christiani,R.M Reis,D Zaridze,A Andrew,A Chang,S.S Shete,C Chen,M.B Schabath,H Brenner,W Xu,Mingdu Dong ,S Schmid,G Liu,A Tardon,R Hung

doi:10.1016/j.annonc.2022.07.1070

945P Respiratory and cardiometabolic comorbidities and stage I-III non-small cell lung cancer (NSCLC) survival: A pooled analysis from the International Lung Cancer Consortium (ILCCO)

M García Pardo De Santayana, Z Jie + Show 18 more

Open Access

https://doi.org/10.1016/j.annonc.2022.07.1070

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Sep 1, 2022
License type: publisher-specific-oa

#International Lung Cancer Consortium #Lung Cancer Specific Survival + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

We explored the association of respiratory and cardiometabolic comorbidities with NSCLC overall survival (OS) and lung cancer specific survival (LCSS), by stage, in a large, international, multi-continent NSCLC pooled dataset.

Full Text